TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Results Conference Call August 15, 2023 11:00 AM ET

Company Participants

Corey Davis - IR, LifeSci Advisors

Dr. Harlan Weisman - CEO

Dr. Zamaneh Mikhak - Chief Medical Officer

Kirk Coleman - CFO

Conference Call Participants

Jonathan Aschoff - ROTH MKM

Justin Walsh - JonesTrading

Vernon Bernardino - H.C. Wainwright

Daniel Carlson - Tailwinds

Operator

Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.

I will now turn the call over to your host, Corey Davis of LifeSci Advisors. You may begin your conference.

Corey Davis

Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals second quarter 2023 corporate update and earnings conference call. With me on the line this afternoon are Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals; Dr. Zamaneh Mikhak, Chief Medical Officer; and Kirk Coleman, Chief Financial Officer.

Before we get started, I would like to remind everyone that this call will contain forward-looking statements, including, without limitation, statements about the anticipated timing of achievement of clinical milestones, the potential to see positive effects in our Phase 2 studies, the number of treated patients necessary to make our decisions in regards to moving to Phase 3 studies, the market opportunity for our product candidates, and the expected time frame for funding operations with cash and cash equivalents.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in all of our findings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2022 annual report on Form 10-K filed with the SEC.

And now, it’s my pleasure to turn the call over to Dr. Harlan Weisman. Harlan?

Dr. Harlan Weisman

Thank you, John, and good morning, everyone, and thank you for joining us for our second quarter 2023 Corporate Update and Earnings Conference Call.

On today’s call, I’m going to review the significant progress that we’ve made over the first half of 2023 and then provide an outlook on what we expect to achieve for the remainder of the year. Following my remarks, our Chief Medical Officer; Dr. Zamaneh Mikhak will provide an update on TFF clinical stage programs. Our Chief Financial Officer, Kirk Coleman, will then review our financial results for the second quarter. We’ll then open up the call for Q&A.